Shanghai Pharma (601607.SH) Stock Community - Hot Topic Discussions - Longbridge

Quote List Quote List

Event Tracking

Dec5

Shanghai Pharmaceutical Terminates Cooperation Agreement with Shengnuo Biotechnology for Novel Acid Inhibitor X842

09:36

Nov28

Shanghai Pharmaceutical Subsidiary's Tramadol Hydrochloride Injection Passes Consistency Evaluation

08:26

Nov11

HSBC Research Maintains Ratings for Shanghai Pharmaceuticals and Sinopharm with Target Price Adjustments

02:53

Nov10

Shanghai Pharmaceuticals Subsidiary's Eslicarbazepine Acetate ANDA Approved by FDA

07:36

Nov6

Shanghai Pharmaceutical Subsidiary Obtains Registration Certificate for Tofacitinib Citrate Extended-Release Tablets

09:09

Shanghai Pharmaceuticals Subsidiary's Ticagrelor Tablets Approved by FDA for US Market

09:09

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 73.48 B, Net Income 688.2 M, EPS 0.1863

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 70.83 B, Net Income 3.126 B, EPS 0.8393

Jul18

Distribution Plan(CST)

Cash dividend 0.29 CNY

View More

Stock List

Top Gainers

Top Decliners

Northbound Connect

Symbol

Price

%Chg

Change

View More